REFERENCES
1. Fouad Y, Dufour JF, Zheng MH, et al. The NAFLD-MAFLD debate: is there a consensus-on-consensus methodology? Liver Int 2022;42:742-8.
2. Fouad Y, Elwakil R, Elsahhar M, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int 2021;41:255-60.
3. Méndez-Sánchez N, Zheng MH, Kawaguchi T, Sarin SK. Editorial: the metabolic (dysfunction) associated fatty liver disease (MAFLD)-non-alcoholic fatty liver disease (NAFLD) debate: a forced consensus and the risk of a world divide. Med Sci Monit 2022;28:e938080.
4. Fouad YM, Gomaa A, El Etreby RM, AbdAllah M, Attia D. Editorial: the metabolic (dysfunction)-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) debate: why the american association for the study of liver diseases (AASLD) and European association for the study of the liver (EASL) consensus process is not representative. Med Sci Monit 2022;28:e938066.
5. Malhi H, Brown RS Jr, Lim JK, et al. Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: Implications for and expectations of AASLD journals. Liver Transpl 2023;29:1262-3.
6. Shiha G, Korenjak M, Eskridge W, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol 2021;6:73-9.
7. Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol 2024;80:e74-6.
8. Alboraie M, Fouad Y, Eslam M. Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective? Hepatology 2024;Online ahead of print.
9. Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol 2021;6:864-73.
10. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73:202-9.
11. Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020;158:1999-2014.e1.
12. Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020;14:889-919.
13. Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol 2022;19:638-51.
14. Kurtulmuş F. The democratization of science. Global Epistemologies and Philosophies of Science. London: Routledge; 2021. pp. 145-54.
15. Carolan MS. Science, expertise, and the democratization of the decision-making process. Soc Natur Resour 2006;19:661-8.
16. Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022;7:388-90.
17. Méndez-Sánchez N, Maris-Gil S, Alonso-Rivera CG. Latin American association of pediatrics (ALAPE) endorses the MAFLD definition of fatty liver disease. J Hepatol 2022;77:249.
18. Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol 2021;75:454-61.
19. Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64.
20. Spearman CW, Desalegn H, Ocama P, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J Hepatol 2021;74:1256-8.
21. Berlivet L, Löwy I. Hydroxychloroquine controversies: clinical trials, epistemology, and the democratization of science. Med Anthropol Q 2020;34:525-41.
22. Moss SF. The great ulcer war: how it all happened. Available from: https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2815%2900584-3 [Last accessed on 29 May 2024]
23. Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gut 2015;64:1671-2.
